ISPE
SEPTEMBER 29, 2023
For more than 240 years, Takeda has focused on delivering transformative treatments in the therapeutic areas of gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
European Pharmaceutical Review
OCTOBER 12, 2023
September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. The pharmaceutical company stated it will establish the first industrial-scale supply of biomethane. The Dunboyne facility is the company’s first biologics drug substance single-use commercialisation facility.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 16, 2023
Rapid growth is forecasted from 2023 onwards: some industry observers predict that the global POC and rapid Dx market projected to reach $75bn by 2027, up from $45bn in 2022, at a CAGR of 10.7%. The fundamental engine of innovation for the global pharmaceutical industry continues. Innovation will power the market.
pharmaphorum
JANUARY 6, 2022
IQVIA Institute models global cumulative spend on COVID-19 vaccines to be a base case of $251bn to 2026 , with spend on COVID-19 treatments, including the new oral agents and treatments of post-viral syndromes, likely to add significant incremental spend. Medicine budget constraint, structural fund largesse.
Pharmaceutical Technology
APRIL 24, 2023
Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures. As a result, some pharmaceutical companies are turning to third parties.
Expert insights. Personalized for you.
52 
Let's personalize your content